The 36-month beta value for GLYC is at 2.20. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GLYC is 58.36M, and currently, shorts hold a 2.73% of that float. The average trading volume for GLYC on April 11, 2024 was 371.95K shares.
GLYC) stock’s latest price update
GlycoMimetics Inc (NASDAQ: GLYC) has experienced a decline in its stock price by -8.58 compared to its previous closing price of 2.68. However, the company has seen a fall of -11.39% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-21 that GlycoMimetics (GLYC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
GLYC’s Market Performance
GlycoMimetics Inc (GLYC) has experienced a -11.39% fall in stock performance for the past week, with a -4.30% drop in the past month, and a -18.87% drop in the past quarter. The volatility ratio for the week is 8.06%, and the volatility levels for the past 30 days are at 8.22% for GLYC. The simple moving average for the past 20 days is -12.93% for GLYC’s stock, with a 19.58% simple moving average for the past 200 days.
Analysts’ Opinion of GLYC
Many brokerage firms have already submitted their reports for GLYC stocks, with CapitalOne repeating the rating for GLYC by listing it as a “Overweight.” The predicted price for GLYC in the upcoming period, according to CapitalOne is $12 based on the research report published on December 22, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see GLYC reach a price target of $4, previously predicting the price at $3. The rating they have provided for GLYC stocks is “Buy” according to the report published on November 12th, 2021.
ROTH Capital gave a rating of “Buy” to GLYC, setting the target price at $12 in the report published on November 14th of the previous year.
GLYC Trading at -16.82% from the 50-Day Moving Average
After a stumble in the market that brought GLYC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.59% of loss for the given period.
Volatility was left at 8.22%, however, over the last 30 days, the volatility rate increased by 8.06%, as shares sank -6.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.44% lower at present.
During the last 5 trading sessions, GLYC fell by -11.39%, which changed the moving average for the period of 200-days by +31.02% in comparison to the 20-day moving average, which settled at $2.81. In addition, GlycoMimetics Inc saw 3.81% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GLYC starting from Rock Edwin, who purchase 30,403 shares at the price of $1.38 back on Sep 22 ’23. After this action, Rock Edwin now owns 375,403 shares of GlycoMimetics Inc, valued at $41,956 using the latest closing price.
Rock Edwin, the Chief Medical Officer of GlycoMimetics Inc, purchase 35,000 shares at $1.38 during a trade that took place back on Sep 21 ’23, which means that Rock Edwin is holding 345,000 shares at $48,300 based on the most recent closing price.
Stock Fundamentals for GLYC
Current profitability levels for the company are sitting at:
- -984295.8 for the present operating margin
- -81.21 for the gross margin
The net margin for GlycoMimetics Inc stands at -3631.86. The total capital return value is set at -255.79. Equity return is now at value -90.73, with -75.98 for asset returns.
Based on GlycoMimetics Inc (GLYC), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -43.15. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is 16912.88.
Currently, EBITDA for the company is -39.12 million with net debt to EBITDA at 0.0. When we switch over and look at the enterprise to sales, we see a ratio of 11691.91. The receivables turnover for the company is 0.06for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.41.
Conclusion
In conclusion, GlycoMimetics Inc (GLYC) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
